Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|May 1, 1995
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancerM Bontenbal, A S Planting, J Verweij, et al.
British Journal of Cancer|June 1, 1995
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanomaW H Kruit, S H Goey, F Calabresi, et al.
British Journal of Cancer|March 25, 2000
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working PartyC M van Herpen, R L Jansen, W H Kruit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor responseW H Kruit, R L Bolhuis, S H Goey, et al.
Cancer|November 15, 1994
Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complicationW H Kruit, K J Punt, S H Goey, et al.
British Journal of Cancer|July 29, 1999
A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervixR de Wit, J van der Zee, M E van der Burg, et al.
British Journal of Cancer|September 1, 1996
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanomaW H Kruit, C J Punt, S H Goey, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 1, 1997
High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancerW H Kruit, S H Goey, C H Lamers, et al.
British Journal of Haematology|February 13, 2001
Interleukin 12 induces activation of fibrinolysis and coagulation in humansJ E Portielje, W H Kruit, A J Eerenberg, et al.
British Journal of Haematology|October 1, 1991
Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanomaW H Kruit, S H Goey, J R Monson, et al.
Pageof 3